SCHEMBL632936

SCHEMBL632936

CC(C)(C)OC(=O)N1CCC(CS(=O)(=O)c2nnnn2-c2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.47
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
STS P08842 1/20 0.43
LMNA P02545 3/20 0.43
MAPT P10636 3/20 0.43
ALDH1A1 P00352 2/20 0.43
POLB P06746 1/20 0.43
TP53 P04637 2/20 0.42
THRB P10828 2/20 0.42
TGFBR1 P36897 1/20 0.42
KAT7 O95251 1/20 0.42
KAT8 Q9H7Z6 1/20 0.42
USP30 Q70CQ3 3/20 0.42
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
LIMK2 P53671 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2414647 0.86 ALDH1A1 (0.48) LMNAMAPTALDH1A1TP53
SCHEMBL2416198 0.81 ALDH1A1 (0.50) LMNAMAPTALDH1A1TP53
SCHEMBL3249302 0.80 GPR119 (0.41) GPR119STSLMNAMAPTALDH1A1
SCHEMBL2413883 0.79 ALDH1A1 (0.52) LMNAMAPTALDH1A1POLBTP53
SCHEMBL3250607 0.79 GPR119 (0.38) GPR119STSLMNAMAPTALDH1A1
SCHEMBL2540015 0.79 DRD2 (0.48) LMNAMAPTALDH1A1POLBTP53
SCHEMBL2540017 0.79 DRD2 (0.48) LMNAMAPTALDH1A1POLBTP53
SCHEMBL27158621 0.76 KAT7 (0.56) GPR119KDM4EPKMSTSTGFBR1
SCHEMBL19433476 0.76 ALDH1A1 (0.62) LMNAMAPTALDH1A1POLBTP53
SCHEMBL3557759 0.75 GPR119 (0.57) GPR119LMNAMAPTPOLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9505750-B2 5-aminocyclylmethyl-oxazolidin-2-one derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2016-11-29 US disclosed
EP-2245028-B1 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-02-22 EP disclosed
US-20110003789-A1 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2011-01-06 US disclosed
EP-2245028-A1 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-11-03 EP disclosed
WO-2009077989-A1 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003789-A1 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES CNKSR1, KCNH1, CBR3 GPR119 2186/4885KDM4E 646/4885PKM 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.